Developing new antimicrobial therapies to treat resistant Gram-negative infections

Achaogen Pipeline
Stage
ZEMDRI (plazomicin)
For Patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae
Full Prescribing Information here
FDA
Approved
C-Scape
ESBL + Enterobacteriaceae
Phase 1
Novel Aminoglycoside
Enterobacteriaceae, P. aeruginosa, A. baumannii
Preclinical
Small Molecule Discovery Program
Infections due to MDR gram-negative pathogens

Preclinical
Therapeutic Antibody Discovery Program
Infections due to MDR gram-negative pathogens
Other therapeutic antibodies against multiple novel targets (e.g., Nav 1.7 for non-opioid pain)
Preclinical

cUTI: complicated Urinary Tract Infection; MDR: multi-drug resistant; ESBL: extended spectrum beta-lactamases.

Only ZEMDRI® has been approved for commercial use. See full Prescribing Information. All other product candidates are investigational only, potential treatments, and have not been approved for commercial use.